Examination for the effect of combination therapy using SERM and Eldecalcitol for the patients with osteoporosis

Examination for the effect of combination therapy using SERM and Eldecalcitol for the patients with osteoporosis - SERM and Eldecalcitol combination therapy for osteoporosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006027

Enrollment

150

Registered

2011-07-25

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Raloxifene Raloxifene + Alfacalcidol(1.0ug/d) Raloxifene + Eldecalcitol(0.75ug/d)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1)Primary osteoposi patients (2)Patients with informed of consent

Exclusion criteria

Exclusion criteria: (1)Patients with contraindication for the drugs usend in this study (2)Patients who do not agree with the participation of this study

Design outcomes

Primary

Measure	Time frame
Change of bone mineral density	—

Secondary

Measure	Time frame
(1)Number of fracturs occured (2)Vertebral deformity (3)Number of falls (4)Grip power (5)Changes of bone metabolic markers (6)Changes of bone quarity makers (7)Changes of QOL points	—

Countries

Japan

Contacts

Public ContactMuneaki Ishijima

Juntendo Hospital Department of Orthopaedics

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026